Pancreatic surgery showdown: which drug prevents leaks best?

NCT ID NCT03000946

Completed Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether somatostatin is better than octreotide at preventing pancreatic fistulas—a common and serious leak after pancreatic surgery. Researchers enrolled 655 adults undergoing pancreatic surgery and gave one of the two drugs for about a week. The goal was to see which drug reduces the risk of moderate to severe fistulas.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Somatostatin and octreotide
What this could lead to: If somatostatin proves more effective, it could reduce serious complications after pancreatic surgery, improving recovery and lowering healthcare costs.
What could go wrong: This is a completed phase 3 trial, so results are available, but the benefit may be modest or not apply to all surgery types. Both drugs have known side effects like nausea or blood sugar changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pancreatic Fistula

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC SURGERY

Contacts and locations

Locations

Cochin Hospital

Paris, Paris, 75014, France
La Pitié Salpêtrière Hospital

Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.